AKT1 and lung cancer: It is interesting to note that AF (0.25 μM) enhanced ibrutinib activity in EGFR mutant non‐small cell lung cancer cells by inhibiting the expression or phosphorylation of multiple key nodes in Akt/mTOR and MEK/ERK pathways.98